+

TN2019000064A1 - Composition comprising multivalent capsular polysaccharide-transport protein and use thereof - Google Patents

Composition comprising multivalent capsular polysaccharide-transport protein and use thereof

Info

Publication number
TN2019000064A1
TN2019000064A1 TNP/2019/000064A TN2019000064A TN2019000064A1 TN 2019000064 A1 TN2019000064 A1 TN 2019000064A1 TN 2019000064 A TN2019000064 A TN 2019000064A TN 2019000064 A1 TN2019000064 A1 TN 2019000064A1
Authority
TN
Tunisia
Prior art keywords
capsular polysaccharide
composition
transport protein
multivalent
multivalent capsular
Prior art date
Application number
TNP/2019/000064A
Inventor
Hoon Sung Jeh
Tae Hyun Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of TN2019000064A1 publication Critical patent/TN2019000064A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a vaccine composition for preventing pneumococcal diseases and an immunogenic composition against Streptococcus pneumoniae, which contains 13 or 14 types of capsular polysaccharide-carrier protein conjugates.
TNP/2019/000064A 2016-09-06 2017-08-31 Composition comprising multivalent capsular polysaccharide-transport protein and use thereof TN2019000064A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160114591 2016-09-06
PCT/KR2017/009569 WO2018048141A1 (en) 2016-09-06 2017-08-31 Composition comprising multivalent capsular polysaccharide-transport protein and use thereof

Publications (1)

Publication Number Publication Date
TN2019000064A1 true TN2019000064A1 (en) 2020-07-15

Family

ID=61561397

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2019/000064A TN2019000064A1 (en) 2016-09-06 2017-08-31 Composition comprising multivalent capsular polysaccharide-transport protein and use thereof

Country Status (12)

Country Link
KR (1) KR101991457B1 (en)
BR (1) BR112019004303A2 (en)
EA (1) EA201990451A1 (en)
JO (1) JOP20190038B1 (en)
MA (1) MA45283B1 (en)
MX (1) MX2019002552A (en)
MY (1) MY192792A (en)
PH (1) PH12019500377B1 (en)
SA (1) SA519401232B1 (en)
TN (1) TN2019000064A1 (en)
WO (1) WO2018048141A1 (en)
ZA (1) ZA201901969B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210177957A1 (en) 2017-12-06 2021-06-17 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
IL304977A (en) 2018-02-05 2023-10-01 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2019203599A1 (en) * 2018-04-18 2019-10-24 에스케이바이오사이언스 주식회사 Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
JOP20210148A1 (en) 2018-12-19 2023-01-30 Merck Sharp & Dohme Compositions including polysaccharide-protein conjugates of Streptococcus pneumoniae and methods of their use
EP4522208A1 (en) * 2022-05-11 2025-03-19 Pfizer Inc. Process for producing of vaccine formulations with preservatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100376361B1 (en) * 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 How to activate soluble carbohydrates using new cyanating reagents for the production of immunogenic constructs
AU2006235013B2 (en) * 2005-04-08 2011-11-03 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2011262346B2 (en) * 2010-06-04 2014-12-11 Wyeth Llc Streptococcus pneumoniae vaccine formulations
KR102057217B1 (en) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
CN103893751B (en) * 2014-03-26 2016-04-20 天津康希诺生物技术有限公司 A kind of pneumococal polysaccharide Protein Conjugation vaccine and preparation method thereof
CN104069504B (en) * 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 A method of enhancing polysaccharide protein conjugate immunogenicity

Also Published As

Publication number Publication date
ZA201901969B (en) 2019-12-18
WO2018048141A1 (en) 2018-03-15
KR20180027353A (en) 2018-03-14
SA519401232B1 (en) 2022-10-23
BR112019004303A2 (en) 2019-05-28
PH12019500377B1 (en) 2024-05-15
EA201990451A1 (en) 2019-08-30
MY192792A (en) 2022-09-09
KR101991457B1 (en) 2019-09-30
JOP20190038A1 (en) 2019-03-06
MX2019002552A (en) 2019-07-01
JOP20190038B1 (en) 2023-09-17
MA45283A1 (en) 2019-06-28
MA45283B1 (en) 2021-05-31
PH12019500377A1 (en) 2019-10-21

Similar Documents

Publication Publication Date Title
PH12021550318A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL265623A (en) Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
MX371454B (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof.
MX2020002556A (en) Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates.
HK1257816A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3668541A4 (en) Pneumococcal conjugate vaccine formulations
TN2019000064A1 (en) Composition comprising multivalent capsular polysaccharide-transport protein and use thereof
MX371453B (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof.
MX2021014948A (en) METHODS OF TREATING PATIENTS WITH AN IMMUNOGENIC COMPOSITION THAT PROTECTS AGAINST <i>S. PNEUMONIAE</i> SEROTYPE 29.
MX2016003621A (en) Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3.
SG11202007676RA (en) Immunogenic composition comprising staphylococcal antigens
ZA202103560B (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine
PH12018501205A1 (en) Synthetic vaccines against streptococcus pneumoniae serotype 2
TH1701007335A (en) Methods for improving the absorption of conjugated polysaccharide-protein and multivalent vaccine formulations were derived from them.
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载